• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Research Update: Dexamethasone complications in disk disease treatment

August 1, 2009
Joseph Harari, MS, DVM, DACVS

Intervertebral disk disease (IVDD) is the most common neurologic disorder for which dog owners seek treatment.

Intervertebral disk disease (IVDD) is the most common neurologic disorder for which dog owners seek treatment. Therapies for affected animals have included glucocorticoids, muscle relaxants, and narcotic analgesics as well as decompressive surgical procedures. The efficacy and timing of drug and operative protocols are often debated in both human and veterinary patients.

In this retrospective case series involving 161 dogs with IVDD from two veterinary schools, the medical records of dogs receiving dexamethasone and surgery (43 cases) were compared with surgically treated dogs receiving other glucocorticoids (23 cases) or none at all (35 cases). In the other-glucocorticoid group, 17 dogs received methylprednisolone sodium succinate, and six were given prednisolone. Dogs receiving glucocorticoids were all treated within 48 hours of admission. No dog received a glucocorticoid while hospitalized in the university clinic.

Results indicated that dogs receiving dexamethasone were 3.4 times more likely to have diarrhea and 11.4 times more likely to have a urinary tract infection than the other two groups of dogs. No differences were seen in neurologic function among all groups at discharge or recheck evaluations. The authors concluded that using dexamethasone for surgically treated IVDD patients should be reconsidered.

Advertisement

COMMENTARY

The results of this study follow a trend in both human and veterinary medicine with regard to questioning the need and efficacy of administering glucocorticoids in patients with IVDD and documenting the complications of such administration. While limitations exist in evaluating data from a retrospective study involving numerous clinicians in different settings, the data are valuable in making veterinarians and clients aware of the risks of drug therapy for this condition. The study also revealed that although not statistically significant, the dexamethasone-treated dogs had a shorter hospitalization than dogs in the other two groups, and client costs were higher in the nontreatment group compared with other patients. Perhaps future prospective, blinded, and controlled studies will help resolve the therapeutic dilemma for clinicians.

Levine JM, Levine GJ, Boozer L, et al. Adverse effects and outcome associated with dexamethasone administration in dogs with acute thoracolumbar intervertebral disk herniation: 161 cases (2000-2006). J Am Vet Med Assoc 2008;232(3):411-417.

The information in "Research Updates" was provided by Veterinary Medicine Editorial Advisory Board member Joseph Harari, MS, DVM, DACVS, Veterinary Surgical Specialists, 21 E. Mission Ave., Spokane, WA 99202.

Joseph Harari, MS, DVM, DACVS

Related Content:

Neurology
Top dvm360 articles of 2022: #6
Top dvm360 articles of 2022: #6
Top dvm360 articles of 2022: #12
Top dvm360 articles of 2022: #12
Working between the brain and the mind
Working between the brain and the mind

Advertisement

Latest News

CE: Why tapeworms matter

Freshpet and Petco partner launch fresh pet food subscription

AAHA Con heads to San Diego

VHMA announces latest class of CVPMs

View More Latest News
Advertisement